CIRC
CirTran Corp.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$0.34
+12.39%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 799.9M | 435.9M | 442.6M | 401.4M | 1.2K |
| Cost of Revenue | 731.3M | 389.9M | 395.4M | 354.5M | 690.00 |
| Gross Profit | 68.6M | 46.0M | 47.2M | 46.9M | 487.00 |
| Operating Expenses | |||||
| R&D Expense | — | — | — | 2.3M | 1.6M |
| SG&A Expense | 119.8M | 91.3M | 64.0M | 45.4M | 2.5M |
| General & Admin Expense | 34.8M | — | — | 3.5M | 2.5M |
| Selling & Marketing Expense | — | — | — | 42.0M | — |
| Other Expenses | 11.2M | 4.9M | 5.0M | 2.8M | (77.5K) |
| Total Operating Expenses | 131.0M | 96.2M | 69.0M | 50.5M | 4.0M |
| Cost and Expenses | 862.3M | 486.1M | 464.4M | 405.0M | 4.0M |
| Operating Income (EBIT) | (62.4M) | (50.2M) | (21.8M) | (3.6M) | (4.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 44.9K |
| Interest Expense | 13.7M | 9.2M | 12.0M | 17.5M | 90.7K |
| Net Interest Income | (13.7M) | (9.2M) | (12.0M) | (17.5M) | (45.9K) |
| Other Non-Op Income/Expense | (94.1M) | (9.2M) | (108.3M) | (17.6M) | (97.7K) |
| Non-Operating Income (excl Interest) | 12.3M | — | 96.3M | 39.9K | 6.9K |
| EBT (Pre-Tax Income) | (156.5M) | (59.4M) | (130.1M) | (21.2M) | (4.1M) |
| Income Tax Expense | (1.4M) | 34.0K | 5.4M | (5.9M) | — |
| Bottom Line | |||||
| Net Income | (155.1M) | (59.4M) | (135.5M) | (15.3M) | (4.1M) |
| Earnings from Cont. Ops | (155.0M) | (59.4M) | (135.5M) | (15.3M) | (4.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (150.2M) | (59.4M) | (135.5M) | (15.3M) | (4.1M) |
| Per Share | |||||
| Basic EPS | ($1.62) | ($1.08) | ($3.68) | ($24.00) | ($12.38) |
| Diluted EPS | ($1.62) | ($1.08) | ($3.68) | ($24.00) | ($12.38) |
| Revenue Per Share | $9.88 | $7.95 | $12.03 | $631.50 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 81.0M | 54.8M | 36.8M | 635593 | 330648 |
| Diluted Shares Outstanding | 81.0M | 54.8M | 36.8M | 635593 | 330648 |
| Profitability Metrics | |||||
| EBITDA | (130.1M) | (43.6M) | (111.4M) | 1.4M | (3.9M) |
| D&A | 12.7M | 6.6M | 6.7M | 5.0M | 87.9K |
| EBIT | (142.8M) | (50.2M) | (118.1M) | (3.6M) | (4.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026